Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors in the battle against the infections, have been a major focus of research.
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer – Pharmaceutical Technology
Pfizer inherited ADC Tivdak following its high-profile $43bn acquisition of Seagen in 2023. Credit: YES Market Media via Shutterstock. Pfizer and Genmab’s Tivdak (tisotumab vedotin-tftv)
April 30, 2024